#### Preliminary Efficacy for HPTN 094: 26-week RCT of Integrated Strategies for People Who Inject Drugs


Steve Shoptaw<sup>\*</sup>, Nabila El-Bassel<sup>\*</sup>, Philip Andrew, Brett Hanscom, David Goodman-Meza, Irene Kuo, Jordan Lake, Ellen Morrison, Jayla Harris, Tim Skalland, Rahul PaulChoudhrey, Paul Richardson, Jessica Fogel, Melissa Cummings, Dale Burwen, Redonna Chandler, David Metzger and the HPTN 094 Study Team

HPTN HIV Prevention Trials Network

\* Co-Chair

#### **Study Design**






To evaluate if 26 weeks of "one stop" integrated health services supported by peer navigation delivered in a mobile unit is superior to peer navigation alone to "brick and mortar" agencies is superior along **three primary outcomes** 

#### PRIMARY OUTCOMES at 26 Weeks 1. On MOUD 2. ↑ rate of viral suppression for PWH 3. ↑ PrEP among PWoH

#### **Participating Sites**





#### **Study Population**

- 18 and older
- Have opioid use disorder (OUD) and be injecting drugs
- Willing to start OUD treatment, but not currently in treatment
- At risk for transmitting or acquiring HIV
- Living with or without HIV





#### **Peer Navigation**



HPTN 094 peer navigation model draws upon systems theory, self-determination theory, empowerment theory, shared decision-making theory and social support theory to:

- Facilitate Identification and Prioritization of needs and use motivational interviewing techniques to reinforce linkages to appropriate services through 26 weeks
- **Facilitate Retention** in MOUD and harm reduction, HIV care and PrEP through 26 weeks.
- Facilitate Receipt of housing and food support, transportation assistance, other social services at available community resources through 26 weeks

Navigation materials available at: www.hptn.org








HPTN 094 PEER NAVIGATION MANUAL

A research guide for peer-navigators conducting the navigation for the HIV Prevention Trials Network 094 study


INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care

#### **Demographics at Enrollment**



#### **Retention at 26 weeks**





All Participants not Dead or not Incarcerated at Week 26 Visit

6

#### **Primary Outcomes at 26-Weeks**




	PWH (N=38)		PWoH (N=409)	
	Active Control Arm	Intervention Arm	Active Control Arm	Intervention Arm
	n = 17	n = 21	n = 206	n = 203
MOUD using biomarker and prescription	1 (5.9%)	3 (14.3%)	16 (7.8%)	15 (7.4%)
Self-Reported Taking MOUD	5 (29.4%)	7 (33.3%)	37 (18%)	51 (25.1%)
HIV suppression using biomarker	7 (41.2%)	8 (38.1%)		
PrEP detected using biomarkers			6 (2.9%)	11 (5.4%)

2 incident HIV acquisitions, one in each arm. Incidence rate = 1.03 per 100 PY, 95% CI: 0.13, 3.73

#### **All Cause Mortality**




#### **Six-month mortality**



Estimated Hazard Ratio (95% CI): 0.30 (0.08, 1.08), p=0.0661

### A Priori Ambitious Goals





- 50% of participants in the intervention arm are on MOUD at 26 week
- Death rate in the intervention arm is reduced by half, compared to the active control arm
- Twice as many participants in the intervention arm are virally suppressed or on PrEP compared to the active control arm

#### Conclusions on Integrated Care for Addictions and HIV Prevention for PWID



- ✓ ~7-8% PWID started MOUD and continued at 26 weeks. This is significant.
- ✓ Intervention showed 70% reduction of all cause mortality for intervention compared to active control arm, non-statistically significant signal
- A "one stop shop" using a mobile unit to treat PWID at risk for HIV where they are at represents a unique solution for people facing multiple health threats
- Findings provide evidence to support implementation science follow-on study

# Thank you

@HIVptn



nabila@columbia.edu @BasselNabila

> HIV Prevention Trials Network



sshoptaw@mednet.ucla.edu



-

## Acknowledgments



- Overall support for the HIV Prevention Trials Network (HPTN) is provided by the National Institute of Allergy and Infectious Diseases (NIAID), Office of the Director (OD), National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under Award Numbers UM1AI068619-17 (HPTN Leadership and Operations Center), UM1AI068617-17 (HPTN Statistical and Data Management Center), and UM1AI068613-17 (HPTN Laboratory Center).
- The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

